<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925740</url>
  </required_header>
  <id_info>
    <org_study_id>KAUFDNHelal</org_study_id>
    <nct_id>NCT03925740</nct_id>
  </id_info>
  <brief_title>MI and PreviDent Varnish on Non Cavitated Interproximal Lesions.</brief_title>
  <official_title>The Effectiveness of Casein Phosphopeptide Amorphous Calcium Phosphate (MI Varnish) and 5% Sodium Fluoride Plus Xylitol (PreviDent Varnish) on Non Cavitated Interproximal Lesions. Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdulaziz University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdulaziz University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluoride products are proven to be cost effective in preventing dental caries. Newer Fluoride
      products have been released in the market with different components that may have an impact
      on the clinical and radiographic outcome regarding incipient caries management. The objective
      of the study is to compare the effectiveness of PreviDent and MI varnish to (1.23%)
      Acidulated phosphopeptide Fluoride (APF) on remineralisation of non-cavitated proximal
      incipient lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be randomly assigned in three groups by coin toss after obtaining the
      consent form and filling the questionnaire about file number, gender, socioeconomic status,
      education and occupation of the parents and their marital status. Group one will receive MI
      varnish, group two will receive PreviDent varnish, group three will receive 1.23% APF
      standard Fluoride application. The teeth will be cleaned, plaque will be removed, placement
      of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental
      probe followingInternational Caries Detection and Assessment System (ICDAS) score. The
      clinical assessment will be conduct during the application visit initial (T1), three months
      follow up visit (T2) six months follow up visit (T3) and twelve months follow up visit (T3)
      to evaluate the effectiveness of the different types of Fluoride. The radiographic assessment
      will be conducted during (T3) and (T4).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic outcome</measure>
    <time_frame>1 year</time_frame>
    <description>Incipient lesions either remained the same or worsened.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical examination</measure>
    <time_frame>1 year</time_frame>
    <description>Lesion cavitation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>MI Varnish Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PreviDent Varnish Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.23% APF Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular application of APF for 4 minutes with high volume suction to the whole mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MI Varnish</intervention_name>
    <description>Application of MI varnish material versus the standard 1.23% APF.</description>
    <arm_group_label>MI Varnish Group</arm_group_label>
    <other_name>GC MI varnish, Recaldent, primary DI number: D6580052651</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PreviDent Varnish</intervention_name>
    <description>Application of PreviDent Varnish material versus the standard 1.23% APF.</description>
    <arm_group_label>PreviDent Varnish Group</arm_group_label>
    <other_name>Colgate PreviDent varnish ,product DI number: 00038341330937</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.23% APF</intervention_name>
    <description>Standard 1.23% APF application</description>
    <arm_group_label>1.23% APF Control Group</arm_group_label>
    <other_name>ZAP fluoride gel, NDC Number: 24794-0102-16</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is 7-10 mixed dentition

          2. Patients with any incipient non cavitated posterior proximal caries

          3. Patients with any incipient non cavitated anterior proximal cariesanterior

          4. ICDAS Score 1 or 2

        Exclusion Criteria:

          1. Any patients with any serious chronic medical problem.

          2. caries that cross the dentin-enamel junction (DEJ) or enamel discontinuity

          3. history of proximal restorations

          4. history of resin infiltrate

          5. ICDAS score of proximal caries more than two clinically or radiographically.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heba J Sabbagh, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Abdulaziz University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Adbulaziz University Dental Hospital</name>
      <address>
        <city>Jeddah</city>
        <state>Makkah</state>
        <zip>21589</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Abdulaziz University</investigator_affiliation>
    <investigator_full_name>Narmin Helal</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>caries</keyword>
  <keyword>interproximal caries</keyword>
  <keyword>MI varnish</keyword>
  <keyword>PreviDent varnish</keyword>
  <keyword>Fluoride</keyword>
  <keyword>1.23% APF Fluoride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

